Agios Pharmaceuticals (AGIO) Change in Account Payables (2012 - 2026)

Agios Pharmaceuticals has reported Change in Account Payables for 15 years, with the latest figure at -$5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 76.99% year-over-year to -$5.0 million; the trailing twelve-month figure through Mar 2026 stood at -$426000.0 (down 118.13% YoY), and the FY2025 full-year result was $1.7 million, down 73.55% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$5.0 million, down from -$1.1 million in the prior quarter.
• The five-year high for Change in Account Payables was $8.1 million in Q4 2022, with the low at -$9.8 million in Q1 2023.
• Historically, Change in Account Payables has averaged -$114294.1 across 5 years, with a median of -$756000.0 in 2024.
• The largest YoY upside for Change in Account Payables was 436.06% in 2025 against a maximum downside of 297.27% in 2025.
• Agios Pharmaceuticals' Change in Account Payables stood at $8.1 million in 2022, then plunged by 143.8% to -$3.5 million in 2023, then soared by 78.6% to -$756000.0 in 2024, then plunged by 51.46% to -$1.1 million in 2025, then slumped by 336.07% to -$5.0 million in 2026.
• The last three Change in Account Payables figures came in at -$5.0 million (Q1 2026), -$1.1 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.